Patents Examined by Merrell C. Cashion, Jr.
  • Patent number: 5420245
    Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of mammalian farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21.sup.ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. Also disclosed are methods and compositions for the preparation of farnesyl transferase by recombinant means, following the molecular cloning and co-expression of its two subunits, for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21.sup.ras.
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: May 30, 1995
    Assignee: Board of Regents, The University of Texas
    Inventors: Michael S. Brown, Joseph L. Goldstein, Yuval Reiss
  • Patent number: 5409901
    Abstract: The present invention relates to the production of nucleoproteins, more especially DNA, and their use in therapeutic compositions suitable for the treatment of neoplasms, pathological conditions, infections, osteoarticular disorders and the like, which comprise said nucleoproteins as active agent.Similarly, the invention comprises compositions which protect against the harmful effects of radiation and poisons in general, which also comprise said nucleoproteins as active agent.Finally, the present invention relates to a method for treating patients suffering from neoplasms and the like, whereby therapeutically effective quantities of said compositions are administered to the patient.
    Type: Grant
    Filed: November 27, 1989
    Date of Patent: April 25, 1995
    Inventors: Alberto I. Calabrese, Santiago I. E. Calabrese, Juan Nakasone
  • Patent number: 5386014
    Abstract: The present invention relates to chemically modified hemoglobin produced by a novel and efficient method in which stroma-free hemoglobin is first effectively deoxygenated and reduced and then conjugated with a polyalkylene oxide such as polyethylene glycol (PEG) under conditions which maintain the structural integrity of the heme oxygen binding site. In specific, preferred embodiments of the invention, the deoxygenation and reduction is performed under an inert atmosphere by the amino acid cysteine. In additional specific, preferred embodiments, the structural integrity of the heme oxygen binding site is maintained by a high anionic concentration in the reaction mixture. In further preferred specific emodiments of the invention, the polyalkylene oxide is polyethylene glycol; in still further preferred specific embodiments of the invention, the polyalkylene oxide is linked to hemoglobin via a urethane (carbamate) linkage.
    Type: Grant
    Filed: May 22, 1992
    Date of Patent: January 31, 1995
    Assignee: Enzon, Inc.
    Inventors: Kwang Nho, Shmuel Zalipsky, Frank Davis
  • Patent number: 5360928
    Abstract: A compound of the formula ##STR1## or the acid fluoride salts thereof wherein BLK is an N-amino protecting group or hydrogenAA is an amino acid residue andX is H or a protecting group useful as a coupling agent in peptide synthesis.
    Type: Grant
    Filed: October 23, 1989
    Date of Patent: November 1, 1994
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Louis A. Carpino, Dean Sadat-Aalaee
  • Patent number: 5359138
    Abstract: A novel, biologically active substance, poststatin, has been isolated from a culture medium of microorganism belonging to Streptomyces. The novel substance is a peptide compound having a novel structure, wherein the peptide chains have ketone radicals. Thus substance has a high endopeptidase inhibition activity. It is possible to chemically synthesize poststatin related compound having ketone radicals in the peptide chains. These compounds also have an endopeptidase inhibition activity.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: October 25, 1994
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu KaI
    Inventors: Tomio Takeuchi, Takaaki Aoyagi, Masa Hamada, Hiroshi Naganawa, Keiji Ogawa, Machiko Nagai, Yasuhiko Muraoka, Makoto Tsuda
  • Patent number: 5357043
    Abstract: The invention relates to a process for the preparation of an oligopeptide or amino acid alkyl ester.HCl salt, the alkyl group being methyl, ethyl, isopropyl or n-propyl, by converting an oligopeptide.HCl salt or amino acid.HCl salt with an alkanol corresponding to the alkyl group under the influence of an acid catalyst, 0.01-0.5 mol HCl relative to the oligopeptide.HCl salt or amino acid.HCl salt in combination with an acid ion exchange resin being used as acid catalyst.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: October 18, 1994
    Assignee: Holland Sweetener Company V.O.V.
    Inventors: Hubertus J. A. V. Delahaye, Johan T. Tinge, Adelbert A. H. Drinkenburg, Antonius J. J. M. Teunissen, Willem Klop
  • Patent number: 5357041
    Abstract: The present invention relates to peptides from the three type I repeats of human endothelial cell thrombospondin, which bind to sulfated glycoconjugates including heparin and sulfatide. Such peptides are useful in glycoconjugate binding pharmaceutical compositions and in a method for binding glycoconjugates in a subject.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: October 18, 1994
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David D. Roberts, Nenghua Guo, Henry C. Krutzsch
  • Patent number: 5354736
    Abstract: Compositions of the invention include composites comprising a biomaterial carrying compounds with enhanced cell binding with respect to collagen. These composites are useful for soft and hard tissue repair or reconstruction. Suitable compounds with enhanced cell binding include synthetic peptides that mimic the conformation necessary for recognition and docketing of collagen binding species (such as cell surface receptors for collagen and fibronectin). Hydrogel matrices as the biomaterial promote cell attachment to the matrix and cell migration into the matrix.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: October 11, 1994
    Assignee: Regents of the University of California
    Inventor: Rajendra S. Bhatnagar
  • Patent number: 5352771
    Abstract: The present invention provides a method for the selective cleavage of peptide amide bonds under ambient conditions by treating a peptide comprising the subunit --CO--NH--CH((CH.sub.2).sub.x SY)CONH-- wherein x is 1-2 and Y is H or (C.sub.1 -C.sub.4)alkyl in an aqueous medium with a tetracoordinate Pd(II) or tetracoordinate Pt(II) complex which promotes the hydrolysis of the adjacent amide bond proximal to the carboxy terminus of the subunit.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: October 4, 1994
    Assignee: Iowa State University Research Foundation Inc.
    Inventors: Nenad M. Kostic, Longgen Zhu
  • Patent number: 5352770
    Abstract: Disclosed are a novel physiologically active peptide having the following structural formula and an acid addition salt thereof: ##STR1## (where (1)/(2) and (3)/(4) are respectively bonded directly and each of the cysteine residues (Cys) at positions 6 and 22 forms an intramolecular S--S bond).This novel peptide derives from porcine and since it exhibits natriuretic and hypotensive actions, the peptide is useful as a therapeutic for cardiac edema, nephredema, hepatic edema, hypertension, congestive heart failure, acute and chronic renal insufficiency, etc. Further, exhibiting the capability of suppressing the growth of smooth vascular muscle cells and the cGMP producing activity, the novel peptide is anticipated to have the potential for serving as an effective therapeutic for atherosclerosis.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: October 4, 1994
    Inventor: Hisayuki Matsuo
  • Patent number: 5348940
    Abstract: Certain propionitrile compounds which have a cyclohexapeptidyl nucleus and which are found to have antibiotic activity with physical properties suitable for use in therapeutic compositions are described. A novel process for their preparation is also described.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: September 20, 1994
    Assignee: Merck & Co., Inc.
    Inventors: James M. Balkovec, Robert A. Zambias
  • Patent number: 5342922
    Abstract: Novel inhibitors of retroviral protease, e.g., HIV protease, are provided which are peptides having from about 4 to about 8 amino acid residues and which are substrates for said protease derived from known cleavage sites and modified to contain an internal CH.sub.2 NH bond isostere.
    Type: Grant
    Filed: March 8, 1989
    Date of Patent: August 30, 1994
    Assignee: Washington University
    Inventors: Garland R. Marshall, Mihaly V. Toth
  • Patent number: 5340920
    Abstract: A peptide composed of 53 amino acid residues represented by the following amino acid sequence: (see SEQ ID NO: 1) ##STR1## and derivatives thereof represented by the following amino acid sequence: (see SEQ ID NO: 2) ##STR2## wherein X is as shown in the specification, are disclosed. These polypeptides are novel and have natriuretic and hypotensive actions.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: August 23, 1994
    Assignee: Hisayuki Matsuo
    Inventors: Hisayuki Matsuo, Kenji Kangawa, Naoto Minamino
  • Patent number: 5340800
    Abstract: Peptide medicaments, and antibody thereto, useful for treating or preventing diseases, particularly diseases involving an inflammatory response by a host organism against infection, that are preferably derived from the .beta. subunit, CD18, of the leukocyte integrins, and that have the property of either interfering with, or preventing undesirable leukocyte adhesion to biological materials, particular to endothelial cells, or that interfere with, or prevent the chemotaxis of leukocytes through the endothelial cell monolayer, consequently minimizing undesirable cell/tissue leukocyte binding and thus preventing or minimizing diseases resulting therefrom.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: August 23, 1994
    Inventors: David Y. Liu, Zehra Kaymakcalan, Kirsten Mundy
  • Patent number: 5338830
    Abstract: A novel peptide that exhibits a natriuretic action and a vasodepressor activity, and hence, that is applicable as a diagnostic reagent. The novel peptide is manufactured by the procedure of genetic engineering as well as by the methods of purification from chicken brains or by chemical synthesis.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: August 16, 1994
    Assignees: Suntory Limited, Hisayuki Matsuo
    Inventors: Hisayuki Matsuo, Kenji Kangawa, Naoto Minamino
  • Patent number: 5338725
    Abstract: The present invention provides synthetic antiaggregatory agents for preventing inhibition of fibrinogen-platelet binding. These anti-aggregatory agents have the general formulas (1)-(5).H--[--(AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.j --].sub.n --Cx (1)[Ri--C(O)--R--G--D--(AA.sub.j).sub.j --].sub.n --CX (2)Cy--[--AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.i --].sub.n --Z (3)H--[--(AA.sub.i).sub.i --R--G--D--(AA.sub.j).sub.j --].sub.n --CZ--[--(AA.sub.k).sub.k --R--G--D--(AA.sub.l).sub.l --].sub.m --Z (4)[R.sub.1 --C(O)--R--G--D--(AA.sub.i).sub.i --].sub.n --CZ[--(AA.sub.j).sub.j ]--R--G--D--(AA.sub.k).sub.k --].sub.m --Z (5)in which: R=Arg; G=Gly; D=Asp; AA.sub.i, AA.sub.j, AA.sub.k and AA.sub.l = alpha-, beta- and omega-amino acid residues; (AA.sub.i).sub.i (AA.sub.j).sub.j =peptide chains having the same or different amino acid residues; (AA.sub.k).sub.k =peptide chains having the same or different amino acid residues; (AA.sub.l).sub.
    Type: Grant
    Filed: June 30, 1992
    Date of Patent: August 16, 1994
    Assignee: The Research Foundation of the State University of New York
    Inventors: Iwao Ojima, Masakatsu Eguchi, Young-Im Oh, Barry S. Coller
  • Patent number: 5336759
    Abstract: A novel peptide that exhibits a natriuretic action and a vasodepressor activity, and hence, that is applicable for a diagnostic reagent. The novel peptide is manufactured by tile procedure of genetic engineering as well as by the methods of purification from frog brains or by chemical synthesis.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: August 9, 1994
    Assignees: Suntory Limited, Hisayuki Matsuo
    Inventors: Hisayuki Matsuo, Kenji Kangawa, Naoto Minamino
  • Patent number: 5334703
    Abstract: The invention relates to, novel peptide derivatives with the formula: R.sub.1 -A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -R.sub.2 or its salt, wherein R.sub.1 =H or a protective group, A.sub.1 =H, Ile, Leu or Val, A.sub.2 =Glu, Asp, Ser, Thr; A.sub.3 =Gly or Glyc; A.sub.4 =Arg or Lys; R.sub.2 =4-nitroaniline with the proviso that A.sub.3 is Gly when A.sub.4 is Lys and that A.sub.3 is Glyc when A.sub.4 is Arg. The invention also discloses the process for the preparation of the peptide derivatives, the method for the determination of the bacterial endotoxins by the use of the invented peptide derivatives and the use of these derivatives for determination of bacterial endotoxins.
    Type: Grant
    Filed: June 11, 1992
    Date of Patent: August 2, 1994
    Assignee: Chromonogenix AB
    Inventor: Salo Arielly
  • Patent number: 5330973
    Abstract: The present invention is directed to water-soluble derivatives of antibiotic lipopeptides. The derivatives have good solubility properties in aqueous medium, rendering them more useful as therapeutic agents.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: July 19, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Milton L. Hammond, Robert E. Schwartz, James M. Balkovec
  • Patent number: 5326751
    Abstract: A new class of opioid receptor analogs is described based on an alanine substitution in the three position in the enkephalin analog DPDPE. The alanine-substituted analogs show increased selectivity for the delta type of opioid receptors over the mu type of receptors.
    Type: Grant
    Filed: June 26, 1992
    Date of Patent: July 5, 1994
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Ronald C. Haaseth, Victor J. Hruby